Charlotte Girondel
RESEARCH PROJECT
Metabolic rewiring in colorectal cancer liver metastases
Colorectal cancer is the most common human cancer worldwide and approximately 50% of colorectal cancer patients develop liver metastasis. Unfortunately, the majority of the patients with colorectal cancer liver metastases (CRCLM) are ineligible for liver resection. Two main distinct histopathological growth patterns have been described in CRCLM, which are termed encapsulated and replacement type, replacement-type liver metastases being associated with worse prognosis. My research aims to identify metabolic rewiring happening within the liver that promote either encapsulated or replacement-type metastases. By combining metabolomics analyses from in vitro and in vivo models (syngeneic or patient-derived xenograft), molecular and functional approaches, I aim to uncover specific metabolites and metabolic pathways contributing to replacement-type metastasis and identify therapeutic vulnerabilities.
BACKGROUND
I completed my PhD in Pharmacology at Université de Montréal, where I studied the tumor suppressive role of the orphan receptor IL-17RD in colorectal cancer associated with chronic inflammation such as crohn’s disease or colitis. I then joined the Siegel Lab at the Rosalind and Morris Goodman Cancer Institute as a postdoctoral fellow, investigating how metabolic rewiring of colorectal cancer cells can promote liver metastatic progression.
CONTACT INFO
Rosalind and Morris Goodman Cancer Research Centre - McGill University
1160 Pine Ave. West (Room 508)
Montreal, Quebec (Canada)
H3A 1A3
T. 514.398.8889
F. 514.398.6769